Silo Pharma, Inc. (SILO) Form S-3 — Jul 24, 2026
Silo Pharma has filed a Form S-3 registration statement to permit the resale of 1,906,392 shares of common stock by selling shareholders. These shares consist of common stock issued in a July 2026 private placement and shares issuable upon the exercise of related warrants, including Pre-Funded Warrants and Series A-3 and A-4 Warrants. The company will not receive any proceeds from the resale of these shares by the selling shareholders. However, if the warrants are exercised for cash, the company could receive gross proceeds of approximately $8.07 million, which would be used for working capital and general corporate purposes.
Key figures
- Shares Offered
- 1906392
- Shares Outstanding
- 1,252,610
- Reverse split ratio
- 1-for-15
- Common shares offered
- 124000
- Series a3 warrant shares
- 619965
- Series a4 warrant shares
- 619965
- Pre funded warrant shares
- 495965
- Potential warrant proceeds
- $8.07 million
- Net proceeds private placement
- $3.5 million
- Placement agent warrant shares
- 46497
Price after filing
Close on the filing date to close N calendar days later (from $4.47). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.